How Hidden Buyers Decide, and What It Changes About Your Marketing
- Aug 11
- 10 min read
How Do Hidden Buyers Decide?
Hidden buyers, the stakeholders in Legal, IT, Procurement, Finance, Clinical leadership and Regulatory/Quality, hold roughly 50 percent of B2B buying influence, per research from the LinkedIn B2B Institute with Bain. They decide by minimizing risk, not comparing features: forming judgments without the vendor in the room, defaulting to no decision when confidence is thin and approving only what they can defend. Marketing built solely for champions never reaches them. The fix is a verification layer added in doses, not a replacement of champion marketing.
Most healthcare marketing is built for the person who already wants to believe you. The clinical champion who lit up in the demo. The VP who repeats your positioning back to you better than you wrote it. We build decks for that person, nurture sequences for that person, ROI calculators for that person. For years that was the whole playbook, which was fine, until it wasn't anymore.
Because the person who loves your product is almost never the person who approves it. Somewhere between the enthusiastic demo and the signature, your deal passes through hands you never shook. Those hands decide.
The Quietest People in the Deal Carry the Most Weight
How much weight? About half. Research from the LinkedIn B2B Institute with Bain puts roughly 50 percent of buying influence with people outside the formal buying conversation. We call this group the Hidden Buying Committee: the stakeholders in Legal, IT, Procurement, Finance, Clinical leadership and Regulatory/Quality who never take your call, never watch your demo and still hold the authority to end your deal.
The same research explains why the group matters more than any individual in it. Buyers are 20X more likely to purchase when the full buying group already knows the brand. Not when the champion knows you. When the group does. That gap, between the one person you convinced and the six you never reached, is where most healthcare and MedTech deals quietly die.
There is a timing dimension that makes this worse. The Ehrenberg-Bass Institute, in work for the same LinkedIn B2B Institute, estimates that as many as 95 percent of category buyers are out of market at any given moment. They are not evaluating anyone. But they are forming impressions, and those impressions harden into the day-one list: the short set of vendors a buying group considers the moment budget appears. The Buyability research puts numbers on how much that list matters. 81 percent of purchases went to vendors that almost everyone in the buying group already knew, and only 4 percent to vendors known solely by the recommending expert. Which means the deal is largely decided before anyone calls it a deal, by people you have never met, based on what they absorbed while you thought nothing was happening. If the hidden seats have not heard of you when the window opens, you are not losing the deal. You were never in it.
Notice what this is not. It is not a sales process problem your reps can fix with better follow-up. By the time the committee convenes, the selling is over and the judging has begun. What survives that judgment is brand, in the fullest sense of the word: everything the organization can find, verify and defend about you when you are not in the room.
Why They Decide the Way They Do
Start with their incentives, because everything else follows from there.
A champion is rewarded for finding the right answer. A hidden buyer is punished for missing the wrong one. Legal is not scored on the deals it approves. It is scored on the exposure it fails to catch. Procurement gets no credit when a vendor performs and inherits a career problem when one collapses mid contract. Finance owns the number long after your case study math has met reality. For every seat on the committee, a yes carries personal risk and a no carries almost none. That asymmetry is not cynicism. It is the job description.
Now follow the incentive structure to its natural conclusion. The committee rarely needs to reject you. It only needs to not approve you. Matt Dixon and Ted McKenna, analyzing more than 2.5 million recorded sales conversations for "The JOLT Effect," found that between 40 and 60 percent of qualified deals end in no decision at all. Not lost to a competitor. Lost to nothing. And the driver, their data shows, is not attachment to the status quo. It is fear of messing up: the personal risk of backing a choice that goes wrong. Your real competitor at the committee stage is not the other vendor on the shortlist. It is the deeply rational choice to choose nothing.
They also live with the decision longer than anyone else involved. Your champion may change roles within a year of signing. Procurement manages the vendor relationship for the life of the contract. IT maintains the integration through every system migration that follows. Clinical leadership answers for the tool at the bedside. The committee is not evaluating your launch. It is evaluating year three.
Then there is the information environment, and this is the part most marketing teams underestimate. Hidden buyers rarely experience your brand the way you designed it. They meet you through artifacts: a forwarded email, your security page, your documentation, your pricing structure, a search result, a colleague's offhand opinion. They form their judgment in your absence, from whatever evidence is lying around. Gartner has measured how much absence that is. B2B buying groups spend only about 17 percent of the total purchase journey meeting with potential suppliers, and when several vendors are in play, any single seller may get 5 or 6 percent of the group's time. The rest of the decision happens where your campaigns cannot follow. And in that environment, missing information does not read as neutral. It reads as risk. The compliance posture you never published becomes the compliance posture they assume you don't have.
These judgments have one more property worth respecting: they are sticky. A hidden buyer who has filed you under risky rarely reopens the file, because reopening it means re-owning the risk. Every later piece of evidence gets read through the first impression, and disconfirming evidence gets discounted as the exception. First impressions in committee are not a first round. For most vendors they are the whole game.
This is also why peer validation outperforms everything else you can say about yourself. The research finding is stark: recommendations from trusted peers carry roughly 3X the influence of claims about better performance or lower price. The reason is not sentiment. A peer recommendation is transferable defensibility. If the decision goes wrong, "organizations like ours use them" survives internal review in a way "the demo was impressive" never will. Hidden buyers are not choosing the best product. They are choosing the choice they can defend, which is the entire premise behind Buyability, the growth model developed by the LinkedIn B2B Institute with Bain.
Healthcare sharpens this further, because this is an industry with formal structures for peer proof: reference site visits, society meetings, advisory panels and the quiet call between two hospital IT directors that will never appear in any attribution model. When that call happens, your brand is either already in the room or it is not, and no campaign running that week changes the answer.
Six Seats, Six Standards of Proof
The committee is not a monolith, and treating it as one is its own failure mode. Each seat runs a different read on the same brand, against a different fear, with a different definition of proof. Here is how one deal meets six separate judgments.
LEGAL
Your champion forwards the contract on a Friday. By Tuesday, Legal has read more of your website than your champion ever did, and not the pages you hoped. The case study promising a "guaranteed reduction in readmissions" is now an exhibit: an unsubstantiated outcome claim in a regulated category, written by marketing, owned by the organization the moment it signs. The question Legal is asking is not whether your product works. It is whether your words create exposure. What survives this read is substantiated claims, a clean IP story and copy written as if a lawyer will read it, because one will.
IT
The pattern here is the stall. The champion requests your security documentation, your team takes two weeks to assemble what should have existed on day one, and momentum quietly leaves the deal while the questionnaire sits open. Meanwhile IT has already searched for a security page and found nothing, and to this seat nothing means worst case: no encryption story, no breach posture, no business associate agreement ready to sign. What survives is boring and public. A trust page IT can reach without asking, compliance status stated plainly and the agreement drafted before anyone requests it.
PROCUREMENT
Procurement opens a file: financial stability, insurance certificates, references, continuity. For a young company the hardest question in that file is the quiet one. What happens to our data and our workflow if you disappear in 18 months? "We're growing fast" is not an answer. It is a restatement of the risk. There is a second job at this seat too. Procurement often needs a documented reason not to open your deal to competitive bid, and a genuinely differentiated position is that reason. Sameness invites the RFP. What survives is continuity language, transition terms and a claim no lookalike competitor can copy into their own deck.
FINANCE
Your ROI calculator will not be in the room. A rebuilt version of it will, with your assumptions stripped out and theirs put in. If the case only closes on your math, it does not close. Finance is also running a calculation you never see: the cost of defending this line item in next year's budget review, when your champion may no longer be there to defend it. What survives is a model that still works on conservative inputs, third-party benchmarks in place of self-reported ones and one number the champion can say out loud in a budget meeting without a footnote.
CLINICAL LEAD
The clinical champion and the Clinical Lead are rarely the same person, and the difference decides deals. The champion saw the demo. The Clinical Lead asks what the evidence base is, what the workflow burden on staff looks like and what happens at the patient safety edge cases the demo skipped. To this audience a glossy brochure reads as the absence of data wearing good design. What survives is an evidence summary with the study design named, outcomes reported honestly and limitations acknowledged, because in clinical culture the willingness to state a limitation is itself a credibility signal.
REGULATORY/QUALITY
This seat gets mistaken for Legal, and it is not Legal. Legal reads for exposure. Quality reads for process: whether your quality system will hold up inside their audit trail. For a MedTech vendor the questions are concrete. Device classification, clearance status and certifications, stated where an auditor can find them. And for anyone crossing the Atlantic in either direction, whether the posture translates. A US vendor courting a German hospital gets read for MDR readiness. A DACH vendor entering the US gets read for its FDA story. What survives is a stated regulatory position, even a single honest paragraph on the website, because on this page silence is the loudest answer you can give.
One brand, six evidentiary standards. Marketing written for one reader fails the other five by default. We keep the full seat-by-seat map, including what each seat fears and why, as a standing reference on our Hidden Buying Committee page.
The Pivot: From Persuasion to Verification
Here is what this changes in practice.
Most marketing budgets buy persuasion assets: campaigns, content and creative built to generate desire in the champion. That work stays necessary, but the committee does not consume desire. It consumes verification. So the shift is not louder marketing aimed at more people. It is a second layer of marketing with a different job: a public, findable, current answer to each seat's first question, built before any deal needs it.
What makes this harder than it sounds is not the production. It is the register. Each artifact has to be written in the evidentiary language of the seat that reads it, and most fail because marketing writes them the only way marketing knows how: persuasively. A security page that sells is a security page that fails. The same sentence that wins a champion can lose a lawyer. Getting that translation right, seat by seat, is a craft of its own, and it is where self-built verification layers quietly come apart.
None of this looks like marketing as most teams practice it, which is exactly why it works. It is the discipline we describe as Deal Risk Insurance: the brand work that keeps a deal alive in rooms you will never enter. And unlike campaign spend, it compounds. Built once and kept current, it is infrastructure that every deal after it passes through.
Do Not Fire Your Champions
Now the correction to the correction, because teams that discover hidden buyers tend to overswing.
The answer is not to abandon champion marketing. Champions still open doors, create urgency and supply the internal energy a deal needs to move at all. A committee can kill a deal, but it has never once started one. Lose your champion focus and you will have a beautifully defensible brand that nobody ever brings into a building.
More to the point, your champion is your distribution channel into the committee. Hidden buyers may never read your campaign, but they will read what the champion forwards. This is the practical meaning of that Gartner figure from earlier: if the group gives all vendors combined 17 percent of its attention, someone has to carry your case through the other 83, and it will not be you. Which means the most effective hidden-buyer marketing often travels inside a champion's email: the one-page committee brief, the security summary, the evidence digest built to be passed along and to survive scrutiny on arrival. The champion's own question has quietly changed too. It is no longer only "do I want this." It is "can I defend this." The most valuable thing your marketing can hand a champion is not another reason to believe. It is armor.
So the operating principle is dosage, not replacement: champion marketing keeps the energy in the deal, and the verification layer keeps the deal alive. How much of each, in what order and starting with which seat is not a formula you can copy out of a blog post, including this one. The right mix depends on where your deals actually stall, and that is a diagnosis, not a default. What holds everywhere is how you measure it: this work will not show up in lead counts. It shows up as Sales Velocity, in fewer late-stage stalls and committee reviews that conclude instead of drifting.
The Read That Matters
The uncomfortable summary is this. Your brand is already being evaluated by the Hidden Buying Committee, with or without your participation. The only open question is whether the evidence they find was built on purpose. Foundation before facade is not a slogan for us. It is the order of operations this committee enforces on every vendor, whether the vendor knows it or not.
It is also the read we built the Brand Probe to run: how a brand actually lands with the people who never take the meeting. The map above is public on purpose. The read is the harder half, because the one brand you can never see clearly is your own. Start wherever you want, but start before the next deal goes quiet.
Comments